Lawrence Wennogle - Intra Cellular Insider

ITCI -- USA Stock  

USD 20.80  0.17  0.82%

  President
Dr. Lawrence P. Wennogle Ph.D. is Vice President Drug Discovery of IntraCellular Therapies Inc. For the past 33 years Dr. Wennogle was involved in research and development in the pharmaceutical industry aimed at the discovery of novel pharmaceutical entities for human diseases. He was a Staff Scientist and Principal Research Fellow at CibaGeigy and Novartis Pharmaceutical Corporationrationration for 19 years where he led drug discovery programs for CNS disorders cardiovascular diseases diabetes and inflammation
Age: 65  President Since 2014  Ph.D    
646-440-9333  http://www.intracellulartherapies.com
Wennogle received his B.A. from Ithaca College and his Ph.D. in Biochemistry from the University of Colorado, Boulder. He then completed two postdoctoral positions, one at the University of Colorado and the second at the Pasteur Institute in Paris, France, working under JeanPierre Changeux on the structurefunction of the nicotinic acetylcholine receptor.

Management Efficiency

The company has return on total asset (ROA) of (17.14) % which means that it has lost $17.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.39) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.

Intra Cellular Thera Leadership Team

Lawrence Wennogle, Vice President of Drug Discovery
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Independent Director
Richard Lerner, Director
Robert Davis, Senior Vice President and Chief Scientific Officer
Allen Fienberg, Co-Founder and VP of Bus. Devel.
Michael Halstead, Sr. VP, General Counsel and Secretary
Sharon Mates, Co-Founder, Chairman, CEO and Pres
Andrew Satlin, Executive Vice President and Chief Medical Officer
Juan Sanchez, Vice President - Corporate Communications and Investor Relations
Rory Riggs, Independent Director
Joel Marcus, Director
Kimberly Vanover, VP of Clinical Devel.
Lawrence Hineline, Vice President and CFO

Stock Performance Indicators

Did you try this?

Run Efficient Frontier Now
   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Efficient Frontier

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">